SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABS · IEX Real-Time Price · USD
1.92
-0.12 (-5.88%)
May 20, 2022 4:30 PM EDT - Market closed
Income Statement (Trailing)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Period Ended | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 60.88 | - | 78.36 | - | 55.24 | - | 3.44 |
| Revenue Growth (YoY) | - | 10.21% | - | 2176.74% | - | - | - | - |
| Gross Profit | - | 60.88 | - | 78.36 | - | 55.24 | - | 3.44 |
| Selling, General & Admin | - | 17.09 | - | 10.09 | - | 6.77 | - | 4.1 |
| Research & Development | - | 57.18 | - | 51.79 | - | 27.91 | - | 8.02 |
| Operating Expenses | - | 74.27 | - | 61.89 | - | 34.68 | - | 12.12 |
| Operating Income | - | -13.39 | - | 16.47 | - | 20.56 | - | -8.67 |
| Interest Expense / Income | - | 0.29 | - | 0.33 | - | 0.47 | - | 0.43 |
| Other Expense / Income | 0 | 3.46 | 0 | -0.69 | 0 | -0.03 | 0 | -0.12 |
| Pretax Income | 0 | -17.14 | 0 | 16.84 | 0 | 20.12 | 0 | -8.99 |
| Net Income | - | -17.14 | - | 16.84 | - | 20.12 | - | -8.99 |
| Net Income Common | - | -17.14 | - | 16.84 | - | 20.12 | - | -8.99 |
| Shares Outstanding (Basic) | 43 | 27 | 35 | 35 | 26 | 25 | 35 | 35 |
| Shares Outstanding (Diluted) | - | 27 | - | 35 | - | 27 | - | 35 |
| Shares Change | - | 1.21% | - | 0.00% | - | - | - | - |
| EPS (Basic) | - | -0.63 | - | 0.72 | - | 0.79 | - | -0.26 |
| EPS (Diluted) | - | -0.63 | - | 0.67 | - | 0.74 | - | -0.26 |
| Free Cash Flow Per Share | - | -0.26 | - | -0.10 | - | -0.11 | - | -0.28 |
| Gross Margin | - | 100.00% | - | 100.00% | - | 100.00% | - | 100.00% |
| Operating Margin | - | -22.00% | - | 21.02% | - | 37.22% | - | -252.01% |
| Profit Margin | - | -28.16% | - | 21.49% | - | 36.42% | - | -261.09% |
| Free Cash Flow Margin | - | -11.80% | - | -4.60% | - | -4.92% | - | -285.41% |
| EBITDA | - | -15.2 | - | 18.08 | - | 21.14 | - | -8.23 |
| EBITDA Margin | - | -24.96% | - | 23.08% | - | 38.26% | - | -239.25% |
| EBIT | - | -16.85 | - | 17.16 | - | 20.59 | - | -8.56 |
| EBIT Margin | - | -27.68% | - | 21.90% | - | 37.27% | - | -248.64% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).